

- Balance
 anatomy and physiology of, 162
 disorders of, 162, 164. *See also* Fall(s) standing, 162
- Balanitis, 1343, 2174
- Balantidium coli*/balantidiasis, 246e-9, 1409
- Bald tongue, 241t
- Bálint's syndrome, 181, 209, 2575
- Balkan nephropathy, 577, 1804, 1856t, 1861
- Balloon angioplasty
 carotid, 2571–2572
 coronary, 296e-1, 296e-1f. *See also* Percutaneous coronary interventions (PCI)
- Balloon expulsion test, 274
- Balloon tamponade, 2064
- Balloon valvuloplasty, 296e-4, 1526
- Baló's concentric sclerosis, 441e-27–28f. *See also* Multiple sclerosis (MS)
- Balsalazide, 1959, 1959t
- Baltic myoclonus (Unverricht-Lundborg disease), 451e-3t
- “Bamboo spine,” 2169
- Banana spider, 2748
- Band(s), in peripheral blood smear, 81e-1–2
- Bangladesh, 13e-3f, 13e-6
- Bangui virus, 1306t
- Banna virus, 1310t
- Bannwarth's syndrome, 907t, 1150
- Barbiturates
 adverse effects of
 cross-sensitivity and, 385
 cutaneous, 360, 361
 folate deficiency, 646t
 hypersensitivity, 382. *See also* Drug-induced hypersensitivity syndrome (DIHS)
 hypothermia, 478e-1
 mitochondrial defects and, 85e-9
 drug interactions of, 42t, 103e-9t
 for epilepsy, 2556
 overdose/poisoning with, 473e-10t
- Bar-coding, of medications, 12e-2
- BARDA (Biomedical Advanced Research and Development Authority), 261e-10
- Bardet-Biedl syndrome
 clinical features of, 415e-4, 1850t, 1855, 2256
 genetic considerations in, 415e-4, 1850t, 1855
 pathophysiology of, 1851f
- Bariatric surgery
 complications of, 2398, 2691
 hypoglycemia after, 569, 2434
 for metabolic syndrome, 2453
 for NALFD, 2057
 outcomes of, 2398
 procedures for, 2398, 2398f
 for type 2 diabetes mellitus, 2417
- Baricitinib, 2218t
- Barium radiography
 in colorectal cancer, 541f
 for colorectal cancer screening, 540
 in constipation, 273
 in dysphagia, 257
 in malabsorption syndromes, 1938, 1939f
 in nausea and vomiting, 260
 in peptic ulcer disease, 1919, 1919f
- Bark scorpion, 2748
- Barlow's syndrome. *See* Mitral valve prolapse
- Barmah Forest virus infection, 837, 1306t, 1313
- Baroreceptors, 142, 143f, 332e-10, 1613
- Baroreflex, 1613
- Barotrauma
 in divers, 477e-6–7
 in hyperbaric oxygen therapy, 477e-2
 in mechanical ventilation, 1743
 sinusitis and, 226
- Barrel chest deformity, 1443
- Barrett's esophagus/metaplasia
 dysplasia in, 1907, 1908f
 endoscopic findings in, 1881, 1882f, 1894–1895, 1907, 1907f
 endoscopic treatment of, 346e-1v
 esophageal cancer and, 262, 533, 1907–1908, 1907f
- GERD and, 262, 1894–1895, 1907
 in systemic sclerosis, 2161
- Barth's Index, 78t
- Barth's syndrome, 375e-1
- Bartonella* spp., 765t, 1078, 1079t, 1083
- Bartonella* spp. infections
 arthritis, 834
 bacillary angiomatosis. *See* Bacillary angiomatosis
 bacillary peliosis, 1081t, 1082–1083
 Carrión's disease, 1081t, 1083
 cat-scratch disease. *See* Cat-scratch disease
 endocarditis, 816, 817, 823t, 824, 1081t, 1082
 global considerations in, 1082
 in HIV infection, 1252t
 Oroya fever, 1081t, 1083
 trench fever, 1080–1082, 1081t
 verruga peruana, 829, 1081t, 1083
- Barter's syndrome
 antenatal, 306
 classic, 306
 clinical features of, 295, 306, 332e-8, 2483
 differential diagnosis of, 321
 genetic considerations in, 306, 332e-7t, 332e-8, 2461
 with sensorineural deafness, 332e-7t
 subtypes of, 332e-7t, 2483
- Basal cell carcinoma (BCC)
 clinical features of
 color, 364–365, 364t
 distribution, 341t, 342f, 500
 morphology, 76e-5f, 341t, 500, 501f
 epidemiology of, 500
 etiology of, 500
 genetic considerations in, 101e-6t, 500
 metastatic, 501
 micronodular, 500
 morpheiform (fibrosing), 500
 natural history of, 501
 nodular, 500
 pathophysiology of, 387, 500, 500f
 pigmented, 500
 prevention of, 502
 risk factors for, 500
 screening for, 483
 sun exposure and, 387, 500
 superficial, 500
 treatment of, 102e-5t, 386, 500, 500f, 501–502
- Basal cell nevus syndrome. *See* Gorlin's syndrome (nevoid basal cell carcinoma syndrome)
- Basal energy expenditure, 462
- Basal ganglia, 2611f, 2613, 2613f
- Basal meningitis, 906
- Basal (resting) metabolic rate, 73, 74f, 415e-2, 461
- BASDAI (Bath Ankylosing Spondylitis Disease Activity Index), 2171
- Baseline Dyspnea Index, 47e-2
- Basement membrane syndromes, 1835t, 1836, 1846
 Alport's syndrome. *See* Alport's syndrome
 antglomerular basement membrane disease. *See* Antiglomerular basement membrane (anti-GBM) disease
 Goodpasture's syndrome. *See* Goodpasture's syndrome
 nail-patella syndrome, 1835t, 1847
 pathogenesis of, 1846–1847
 thin basement membrane disease, 294, 1835t, 1847
- BASFI (Bath Ankylosing Spondylitis Functional Index), 2171
- Basic activities of daily living (ADLs), 72t
- Basic fibroblast growth factor (bFGF), 102e-14, 102e-15f, 1912, 2265
- Basic life support, for cardiac arrest, 1768
- Basilar artery occlusion, 220, 2577–2579, 2577–2580f
- Basilar skull fracture, 457e-2
- Basiliximab, 372e-30, 1517
- Basket cells, 702
- Basophil(s)
 in adaptive immunity, 372e-7t
 hematopoietic differentiation of, 89e-3f
 in innate immunity, 372e-7t, 372e-8–9, 372e-14f
 mediators released from, 372e-15t
 morphology of, 416f
 in peripheral blood smear, 81e-1, 81e-6f
- Basophilic stippling, 657, 659
- Basophil kallikrein of anaphylaxis (BK-A), 372e-15t
- Bassen-Kornzweig disease, 206, 2630
- Batai virus, 1308t
- Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), 2171
- Bath Ankylosing Spondylitis Functional Index (BASFI), 2171
- Bath salts (synthetic cathinones), 469e-3–4
- Battlefield injuries. *See* War veterans
- Battle sign, 457e-2
- BAX, 103e-6, 103e-23, 444e-9
- Bayes' rule (theorem), 3, 21–22, 23f
- Baylisascaris procyonis* infections
 chronic meningitis, 908t
 diagnosis of, 245e-3t, 765t
 encephalitis, 896
 epidemiology of, 245e-3t, 765t
 life-cycle hosts of, 245e-3t
 visceral larva migrans in, 1411
- Bayou virus, 1307t
- Bazedoxifene, 2383, 2499
- Bazex-Dupré-Christol syndrome, 500
- BCC. *See* Basal cell carcinoma (BCC)
- B cell(s)
 deficiencies of, 375e-2, 2104t, 2110f, 2111
 in agammaglobulinemia. *See* Agammaglobulinemia
 in common variable immunodeficiency, 2111
 diagnosis of, 2111
 in hyper-IgM syndrome, 2110, 2110f, 2111
 in IgA deficiency, 2111–2112
 in selective antibody deficiency to polysaccharide antigens, 2112
 definition of, 372e-1
 development of, 372e-17f, 372e-20
 differentiation of, 89e-3f, 697–698, 698f, 710
 functions of, 372e-19–21
 in HIV infection, 1237–1238
 Ig gene rearrangement and, 372e-20–21
 locations of, 372e-19
 monoclonal antibodies to, 372e-30–31
 in rheumatoid arthritis, 2143
- B-cell activating factor, 2166
- B-cell chronic lymphoid leukemia (CLL)/small lymphocytic lymphoma, 701
 anemia in, 393
 approach to the patient, 700
 clinical features of, 702t
 diagnosis of, 695t, 701–702
 epidemiology of, 695, 696f
 genetic considerations in, 699, 699t
 hypogammaglobulinemia in, 492
 immunology of, 698f, 699
 infections in, 484t, 485, 486t, 488
 lymphadenopathy in, 408
 lymphoid disorders that can present as, 695t
 mu heavy chain disease in, 719
 paraneoplastic syndromes in, 618
 peripheral blood smear in, 81e-10f, 702f
 prognosis of, 700
 pure red cell aplasia in, 668
 renal involvement in, 1859
 skin manifestations of, 372
 splenomegaly in, 411
 staging of, 700t
 treatment of, 703
 biologic therapy, 103e-21
 gene therapy, 91e-4
 HSCT, 139e-5t, 139e-6
 rituximab, 102e-5t, 102e-6, 103e-21, 703
 tumor markers in, 135e-2t
- B-cell prolymphocytic leukemia, 135e-1, 135e-2t
- B-cell prolymphocytic lymphoma, 706